TECHNICAL SPECIFICATIONS

Drug / Excipient Delivery System

Drug Sirolimus Delivery System RX/Monorail
Drug Dose 0.7 µg/mm² Nominal Pressure 8 Bar
Drug Carrier Customized biodegradable polymer matrix Rated Burst Pressure 14 Bar*
Guidewire Compatibility (max) 0.014’’
Guiding Catheter Compatibility 5F
Stent Crossing Profile** 0.038‘’
Tip Entry Profile 0.016’’
Stent Material L605 Cobalt Chromium Alloy
Strut Thickness 73 µm
Strut Width 80 µm (hinge) - 120µm (strut) * Do not exceed RBP
** Reference diameter of 3.00 mm

ORDERING INFORMATION
Stent Dia Stent Length (mm)
(mm) 08 12 16 20 24 28 32 36 40 44 48 52
2.25 EAB22508 EAB22512 EAB22516 EAB22520 EAB22524 EAB22528 EAB22532 EAB22536 EAB22540 - - -
2.50 EAB25008 EAB25012 EAB25016 EAB25020 EAB25024 EAB25028 EAB25032 EAB25036 EAB25040 EAB25044 EAB25048 EAB25052
2.75 EAB27508 EAB27512 EAB27516 EAB27520 EAB27524 EAB27528 EAB27532 EAB27536 EAB27540 - - -
3.00 EAB30008 EAB30012 EAB30016 EAB30020 EAB30024 EAB30028 EAB30032 EAB30036 EAB30040 EAB30044 EAB30048 EAB30052
3.50 EAB35008 EAB35012 EAB35016 EAB35020 EAB35024 EAB35028 EAB35032 EAB35036 EAB35040 EAB35044 EAB35048 EAB35052
4.00 EAB40008 EAB40012 EAB40016 EAB40020 EAB40024 EAB40028 EAB40032 EAB40036 EAB40040 EAB40044 EAB40048 EAB40052
4.50 EAB45008 EAB45012 EAB45016 EAB45020 - - - - - - - -
5.00 EAB50008 EAB50012 EAB50016 EAB50020 - - - - - - - -

*The above diagram is just an illustration of the product.

Disclaimer: The law restricts these devices to sale by or on the order of a physician. Indications, contradictions, warnings can be found in the product labelling / IFU supplied with each device. For
DES + DCB* = DES+
restricted use only in countries where product is registered with applicable health authorities. 1434 *drug coating on exposed parts of balloon

Scan for more details

ES.ST.AB.BRO.ver.1.1.21-05
Approved
Indication for
DM and AMI

contact@espl.net.in www.espl.net.in /conceptmedicals

 ABLUMINUS ENVISOLUTION TECHNOLOGY

DIABETES MELLITUS
Patients with DM are more affected by coronary artery disease and when treated by PCI with stent
implantation they remain at higher risk of in-stent restenosis and adverse cardiovascular events. [1-3]

The etiology of this failure is likely to be multifactorial such as diffuse disease progression, small
vessel and endothelial dysfunction. [4-9] ABLUMINAL COATING
Facilitates mono directional drug release
The presence of DM (particularly insulin-treated DM) has been a consistent, independent and less systemic exposure of drug leading
predictor of in-stent restenosis. [10] to faster re-endothelialisation

CELL DESIGN
STENT COMPARISON* Strut thickness (µm) FUSION COATING
10 Drug - Polymer matrix
Coating thickness (µm)
Coating on the stent and exposed parts of
Labelled Diameter the balloon facilitate homogeneous drug
2.25 mm
20 2.50 mm
delivery which addresses diffused
07 06 15 Side Branch Access proliferative disease and focal restenosis
09 04 4.00 mm

6 Cell Design EDGE COATING

Additional 0.5 mm coating
beyond the proximal and distal edge of
ULTIMASTER
ABLUMINUS

BIOMATRIX

INSPIRON

the Stent addresses the edge restenosis

SYNERGY

Labelled Diameter
XIENCE

2.75 mm
ONYX

73 81 81 120 80 74 75 3.00 mm
3.50 mm
* GG Stefanini, M Taniwaki, S Windecker, Coronary stents: novel development, Heart doi:10.1136/heartjnl-2012-303522;
I Meredith, Scientific symposium, TCT 2013; M Rothman, presentation TCT 2014
Side Branch Access BIODEGRADABLE FILM
5.30 mm
The formation of hypothetical circular
film with biodegradable polymer
8 Cell Design due to elasticity of polymer facilitate
Strut Thickness maximum surface area for drug delivery
73 µm
Link Width 60 µm in blood wet conditions DES + DCB* = DES+
Strut Width
120 µm (Strut)
Labelled Diameter Designed to treat
4.00 mm diabetic patients
4.50 mm
Strut Width *drug coating on exposed
5.00 mm parts of balloon
80 µm (Hinge)
Side Branch Access
6.70 mm
References:
1. Kereiakes DJ et al. J Am Coll Cardiol 2010; 56: 2084-9. | 2. Cutlip DE et. al. Circulation 2004; 110: 1226-30. | 3. Lee TT et all Am J Cardiol 2006; 98:718-21. | 4. Morgan KP et al. Heart 2004;
90: 732-8. | 5. Hadi H a R et al. Vasc Health Risk Manag 2007; 3:853-76. | 6. Schalkwijk CG et. Al Clin Sci 2005; 109: 143-59. | 7. Dangas GD et al. J, Am. Coll. Cardiol. 2010; 56:1897-907. | 8.
10 Cell Design Lightell DJ et al. Ochsner J 2013; 13:56-60. | 9. Denardo SJ et al. JAMA 2012; 307:2148-50. | 10. Popma, J.J. et al. Circulation 110, 3773-3780 (2004).